DUBAI, UAE - Sanofi, a global diversified healthcare leader, has launched Enterogermina, a probiotic also known as bacillus clausii that is used to restore the intestinal bacterial balance in case of an intestinal disorder.
Microbiota are microbes that live on the surface of skin, in saliva, eyes and the gastrointestinal tract. The microbiota found in the stomach is to control a person's weight and protect against infection.
"Although we are born with these microorganisms in our bodies, poor dietary habits can disrupt the levels of microbiota in the system and cause more damage than harm," said Dr, Antonio Gasbarrini, M.D from the Internal Medicine Department at Catholic University, Gemelli Hospital, Italy, who presented on the importance of using probiotics in the efforts to maintain a healthy number of bacteria. "Probiotics and postbiotics are part of biotherapy, a new direction in medicine when treating infections and gastric conditions."
Conditions like diabetes, obesity or an inappropriate use of medications such as antibiotics can be linked to adiposity, which occurs when person weight is no longer controlled by these microbes. It is when probiotics can be prescribes to return the balance within the gastrointestinal tract.
"Bacillus clausii is part of a new class of probiotics that help stimulates the immune system to protect the gastrointestinal tract against infection or other gastrointestinal diseases," said Dr. Mohamad Miqdady, M.D., Head of Pediatric Gastroenterology at Sheikh Khalifa Medical City in Abu Dhabi, "Due to the increasing number of diabetes and obesity cases in the UAE, gastrointestinal diseases cases are also on the rise. Probiotics such as Enterogermina, are prescribed as part of the treatment to manage the microbiota in the system."
Enterogermina is now available in the UAE at pharmacies. Speak to a doctor before taking any medications.
About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). Sanofi is present in more than 100 countries, with around 17,000 scientists, to improve health and well being. Global headquarters are in Paris, France, and the Gulf regional office is located in Dubai Health Care City, Dubai UAE.
Contact Details
Lamia Hoteit
W +971 (4) 42 99 220
Lamia.hoteit@sanofi.com
Elissar Amhaz
W + 971 (4) 425 8979
elissar.amhaz@ketchum-raad.com
© Press Release 2013
